What question did this study set out to answer?

To assess the efficacy and safety of tocilizumab in controlling cytokine release syndrome following CD19 CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.

March 14, 2025Frontiers in ImmunologyOpen Access

Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia

View Full Paper

Ask AI

Bookmark

Authors

QZQianyi ZhouTianjin First Center Hospital YAYuxin AnZhejiang Center for Disease Control and Prevention XZXiaomei ZhangShanghai University

Discussion

Member takes

Implication

Retrospective cohort study reveals shortened severe cytokine release syndrome duration with tocilizumab after CAR-T therapy, highlighting its safety without compromising antitumor efficacy.

Key Points

To assess the efficacy and safety of tocilizumab in controlling cytokine release syndrome following CD19 CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.
Retrospective cohort study evaluating 45 patients with relapsed or refractory B-cell acute lymphoblastic leukemia who underwent CD19 CAR-T therapy.
Compared outcomes, cytokine profiles, CAR-T cell expansion, and adverse event frequencies between patients who received tocilizumab (N=17) and untreated controls.
Tocilizumab administration significantly reduced the duration of grade 3 cytokine release syndrome compared with non-treatment, with 10 patients demonstrating reduced cytokine levels.
Treatment with tocilizumab did not impede CAR-T cell expansion or overall therapeutic efficacy, and it did not increase the incidence of adverse events.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/6a712b9af44fa9f079def2fd https://doi.org/10.3389/fimmu.2025.1530623

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort study reveals shortened severe cytokine release syndrome duration with tocilizumab after CAR-T therapy, highlighting its safety without compromising antitumor efficacy.

Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider